The effect of quinapril on functional status of elderly patients with diastolic heart failure

Cardiovascular Drugs and Therapy

Volumn 17, Issue 2, 2003, Pages 133-139

  Zi, Min ^a,c   Carmichael, Neil ^b   Lye, Michael ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b WHISTON HOSPITAL   (United Kingdom)

^c Clinical Department   (United Kingdom)

Author keywords

ACE inhibitor; Ageing; Exercise tolerance; Heart failure

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; QUINAPRIL;

AGE; AGED; AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FATIGUE; FEMALE; HEADACHE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEMODYNAMIC MONITORING; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VERTIGO;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; QUALITY OF LIFE; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; WALKING;

EID: 0141540380     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025387702212     Document Type: Article

References (40)

1. Remes J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart-failure in Eastern Finland - A population-based surveillance study. Eur Heart J 1992;13:588-593.
2. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999;20:421-428.
3. Coats AJS. Is preventive medicine responsible for the increasing prevalence of heart failure? Lancet 1998;352(Suppl 1):39-41.
4. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997;45:968-974.
5. Forman DE, Coletta D, Kenny D, et al. Clinical issues related to discontinuing digoxin therapy in elderly nursing-home patients. Arch Intern Med 1991;151:2194-2198.
6. Swedberg K. Effects of enalapril on mortality in severe congestive-heart-failure - Results of the Cooperative-North-Scandinavian-Enalapril-Survival-Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
7. Ball SG, Cowan JC, Winter C, et al. (The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
8. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: Distribution, signalling and function. Clin Sci 2001;100:481-492.
9. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-942.
10. Rogers TB. High affinity angiotensin II receptors in myocardial sarcolemmal membranes: Characterization of receptors and covalent linkage of 125I-angiotensin to a membrane component of 116,000 daltons. J Biol Chem 1984;259:8106-8114.
11. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptors subtypes in myocardial infarction. J Clin Invest 1995;95:46-54.
12. Weber KT, Sun Y, Katwa LC, Cleutjens JPM. Tissue repair and angiotensin II generated at sites of healing. Basic Res Cardiol 1997;92:75-78.
13. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-1364.
14. Brilla CG, Zhou GP, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-820.
15. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: An appraisal of present experimental and clinical evidence. Circ Res 1991;68:905-921.
16. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: A link to cardiovascular hypertrophy? Hypertension 1991;9:3-15.
17. Nicoletti A, Heudes D, Hinglais N, et al. Left ventricular fibrosis in renovascular hypertensive rats: Effect of losartan and spironolactone. Hypertension 1995;26:101-111.
18. Goldstein S, Sharov VG, Cook JM, Sabbah HN. Ventricular remodeling: Insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors. Mol Cell Biochem 1995;147:51-55.
19. Antonaccio MJ, Kerwin L. Pre- and post-junctional inhibition of vascular sympathetic function by captopril in SHR: Inplication of vascular angiotensin-II in hypertension and antihypertensive actions of captopril. Hypertension 1981;3(Suppl):I54-I62.
20. Purdy RE, Weber MA. Angiotensin-II amplification of alpha-adrenergic vasoconstriction: Role of receptor reserve. Circ Res 1988;63:748-757.
21. Ishise H, Asanoi H, Ishizaka S, et al. Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure. J Appl Physiol 1998;84:1234-1241.
22. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993;71:602-604.
23. McKee PA, Casteili WP, McNamara PM, et al. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971;285:1441-1446.
24. Mader SL. Aging and postural hypotension. An update. J Am Geriatr Soc 1989;37:129-137.
25. O'Keeffe ST, Lye M, Donnellan C, Carmichael DN. Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. Heart 1998;80:377-382.
26. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a six-minute walk test in patients with left ventricular dysfunction. JAMA 1993;270:1702-1707.
27. Shettigar U, Hare T, Gelperin K, et al. Effects of fosinopril on exercise tolerance, symptoms, and clinical outcomes in patients with decompensated heart failure. CHF 1999;5:27-34.
28. Erhardt L, MacLean A, Ilgengaitz J, Gelperin K. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J 1995;16:1892-1899.
29. Dossegger L, on behalf of the Cilazapril-Captopril Multicentre Group. Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: A double-blind, randomised, multicentre trial. Cardiology 1995;86(Suppl 1):34-40.
30. Miller FG. Placebo-controlled trials in psychiatric research: An ethnical perspective. Biol Psychiatry 2000;47:707-716.
31. Harrington D, Anker SD, Coats AJ. Preservation of exercise capacity and lack of peripheral changes in asymptomatic patients with severely impaired left ventricular function. Eur Heart J 2001;22:392-399.
32. Kronenberg MW, Konstam AK, Edens TR, et al. Factors influencing exercise performance in patients with left ventricular dysfunction. J Card Fail 1998;4:159-167.
33. Sunnerhagen KS, Cider A, Schaufelberger M, et al. Muscular performance in heart failure. J Card Fail 1998;4:97-104.
34. Cabanes L, Costes F, Weber S, et al. Improvement in exercise performance by inhalation of methoxamine in patients with impaired left-ventricular function. N Engl J Med 1992;326:1661-1665.
35. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II to III chronic heart failure? Am Heart J 1998;136:449-457.
36. De Bold AJ. Heart atria granularity effects of changes in water-electrolyte balance. Proc Soc Exp Biol Med 1979;161:508-511.
37. Rector TS. Effect of ACE inhibitors on the quality of life of patients with heart failure. Coron Artery Dis 1995;6:310-314.
38. Bulpitt CJ. Quality of life with ACE inhibitors in chronic heart failure. J Cardiovasc Pharmacol 1996;27(Suppl 2):S31-S35.
39. Cowley AJ, Wiens BL, Segal R, et al. Randomised comparison of losartan vs. captopril on quality of life in elderly patients with sympathetic heart failure: The losartan heart failure ELITE quality of life substudy. Qual Life Res 2000;9:377-384.
40. Vasari RS, Benjamin EJ. Diastolic heart failure - No time to relax. N Engl J Med 2001;344(14):56-59.